Anticancer agent 284

Anticancer agent 284 exhibits cytotoxicity against osteosarcoma cell line (Hos), non-small cell lung cancer cell line (A549), and colon cancer cell line (HCT-116) . Anticancer agent 284 can impact the pRIPK3 kinase concentration in the A549 (2.97 pg/mL) . Anticancer agent 284 can be used for the study of cancer[1].

Product Specifications

UNSPSC

12352005

Target

RIP kinase

Related Pathways

Apoptosis

Field of Research

Cancer

Smiles

CC1=CC=C(C=C1)S(=O)(N/N=C(C2=CC=C(C=C2)N/C=C3C(N(N=C/3C)C4=CC=CC=C4)=O)\C)=O

Molecular Formula

C26H25N5O3S

Molecular Weight

487.57

References & Citations

[1]Ahmed AA, et al. Multi-step organic synthesis, cytotoxicity, and molecular docking of new N-phenylpyrazolones incorporated with N-benzylthiazole or N-benzyl-4-thiazolone fragments. Sci Rep. 2025 Sep 29;15 (1) :33340.